Bimekizumab

Bimekizumab (INN[1]) is a monoclonal antibody that is being investigated for ankylosing spondylitis psoriatic arthritis and psoriasis.

Bimekizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetIL17a, IL17f
Clinical data
ATC code
  • none
Identifiers
CAS Number
UNII
KEGG

This drug is being developed by Belgian pharmaceutical UCB. As of 2018, bimekizumab is undergoing Phase III trials.

References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.